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Abstract Mutation of glutamic acid 282 of PPARK to glycine
has been shown to result in an increased EC50 for a wide variety
of PPAR activating compounds. This has suggested that mutant
receptor has a reduced ability to bind ligand. In this study we
show that this mutation reduces the affinity of mPPARK and
hPPARQ for the fluorescent fatty acid, cis-parinaric acid and
that the mutant hPPARQ protein has a reduced affinity for the
radiolabelled compound, SB236636. These data confirm the role
of this glutamic acid in ligand binding and support recent crystal
structure observations regarding a proposed novel mode of ligand
entry into the PPAR ligand binding cavities.
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1. Introduction
The peroxisome proliferator activated receptors (PPAR)
belong to the nuclear receptor family of ligand activated tran-
scription factors. These receptors regulate lipid metabolism in
response to fatty acids and eicosanoids and are targets for
drugs used in the treatment of hyperlipidemia and diabetes.
PPARK is expressed at high levels in the rodent liver and is
activated by the ¢brate family of hypolipidemic drugs [1,2].
PPARK also mediates the pathological e¡ect known as per-
oxisome proliferation caused by these drugs in the rodent
liver. The absolute requirement for PPARK in these events
has been con¢rmed in mouse containing a targeted disruption
of the PPARK gene [3^5]. The PPAR subfamily contains two
other members known as PPARN and PPARQ. The biological
activity of PPARN is relatively obscure, although a role in
embryonic implantation has been proposed [6]. PPARQ, on
the other hand, has been intensively investigated with pro-
posed roles in diabetes [7], atherosclerosis [8], in£ammation
[9], and cancer [10^12]. PPARQ is expressed in adipose tissue
and has been shown to be an important determinant in the
di¡erentiation of adipocytes from ¢broblasts and myoblasts
[13^15]. PPARQ is activated by the isoprostanoid 15-deoxy
v12;14 PGJ2 [16,17] and the thiazolidinedione family of insulin
sensitising drugs [18]. It has recently been proposed that the
action of PPARQ in insulin sensitisation and controlling in-
£ammation is due to the inhibition of the expression of a wide
range of cytokines including TNFK [9,19]. PPARs are molec-
ular switches that bind activating compounds and upon doing
so changes occur in the protein conformation mediating an
increase in the transcription of target genes. In studies with
mouse PPARK, it was noted that PPARK displayed extensive
activation of transcription without the addition of activating
compound and, upon the addition of fatty acids and ¢brate
drugs, only very small responses were observed [20,21]. This
was not the case when a PCR-derived mutant form of PPARK
was used in the same experiments. This mutant, which con-
tained a substitution of a glycine for glutamic acid 282, dis-
played very little transcriptional activation in the absence of
added drugs and responded very well to the addition of fatty
acids and ¢brate drugs. Careful examination of the concen-
tration dependency of the activation of both forms of the
receptor revealed that the mutant receptor required higher
concentrations of all ligands studied for maximal activation
when compared to the wild type protein [20]. This gave rise to
the hypothesis that the GLU282GLY substitution resulted in
a diminished a⁄nity for ligand binding and that this lowered
a⁄nity was no longer su⁄cient to permit activation by the
endogenous ligand that provided the constitutive activation of
the wild type receptor. This observation was supported by the
¢nding that increased levels of ligands were required to stim-
ulate mutant PPARK binding to DNA in a heterodimer with
retinoid X receptor (RXR) [22].
In this study we show that the GLU282GLY substitution in
mouse PPARK leads to a lower e⁄ciency of binding to a
£uorescent fatty acid, cis-parinaric acid (CPA), and that the
corresponding mutation in human PPARQ leads to reduced
binding of both CPA and the high a⁄nity ligand, SB236636.
2. Materials and methods
2.1. Expression of PPAR ligand binding domains (LBD) in Escherichia
coli
The PPAR coding sequences were isolated by the polymerase chain
reaction using primers that generated a NdeI site/ATG initiation co-
don at the 5P end and a BamHI site immediately after the terminator
codon. For mPPARK, nucleotides 674^1573 of GenBank accession
number X57638 were ampli¢ed using the upper primer: GGAATT-
CCATATGGCAATTCGCTTTGGAAGAATGCC and the lower
primer: CGGGATCCTCAGTACATGTCTCTGTAGATCTC. The
resulting sequence encodes amino acid 170^468 of mouse PPARK.
For hPPARN, nucleotides 761^1663 of GenBank accession number
L07592 were ampli¢ed using the upper primer: GGAATTCCA-
TATGGCTATCCGTTTTGGTCGGATG and the lower primer:
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CGGGATCCTTAGTACATGTCCTTGTAGATCTCCTG. The re-
sulting sequence encodes amino acid 142^442 of human PPARN.
For mPPARQ, nucleotides 577^1428 of GenBank accession number
U10374 were ampli¢ed using the upper primer: GGAATTCCATA-
TGGCGGAGATCTCCAGTG and the lower primer: CGGATCC-
TAATACAAGTCCTTGTAGATCTCCTG. The resulting sequence
encodes amino acids 192^475 of mouse PPARQ. The ampli¢ed prod-
ucts were cloned into NdeI/BamHI digested pET15b and transformed
into E. coli strain BL21(DE3) pLYSs. Expression of the His-tagged
LBD was induced with 0.5 mM IPTG at 25‡C for 2 h. Lysates from
these cultures were prepared and the expressed protein puri¢ed by
nickel/agarose a⁄nity chromatography.
2.2. Mutation of a human PPARQ ligand binding domain
The portion of the human PPARQ cDNA encoding the LBD was
isolated by PCR from a human kidney cDNA library (Clonetech) as
previously described [23]. The ampli¢cation product was cloned into
pET15b as described for the other PPAR cDNAs. Oligonucleotide
directed mutagenesis was used to substitute a glycine for a glutamic
acid at codon 291.
2.3. CPA £uorescence assays
Puri¢ed PPAR LBDs were mixed with CPA in 25 mM Tris^HCl
(pH 7.5) at room temperature and the resulting £uorescence was
measured immediately in a Perkin Elmer £uorimeter using a excita-
tion wavelength of 318 nm and an emission wavelength of 410 nm.
The £uorescence resulting from protein alone and CPA alone were
totaled and deducted from the experimental value. Graphs were plot-
ted using Graphpad Prism 2.0 for Macintosh and the data subjected
to a non-linear regression analysis based on a sigmoidal dose re-
sponse. This provided the Kd and standard error. All Kds stated in
the text were obtained using concentrations of ligand between 4 and
10 fold below the EC50 in order to avoid stoichiometric binding.
2.4. Rapid ¢ltration binding assays
Puri¢ed mutant and wild type PPAR LBDs (5 nM) were incubated
with increasing concentrations of I125 labelled SB236636 as previously
described [24]. The mixtures were incubated on ice for 2 h and then
applied to 25 mm Millipore HAWP ¢lters on a vacuum manifold. The
¢lters were washed twice with 5 ml of ice cold binding bu¡er, dried
and the bound radioactivity was determined by liquid scintillation
spectrophotometry. All assays represent means of triplicate samples
minus the value determined for non-speci¢c binding to the ¢lter. The
Kd is calculated as the slope of the Scatchard plot.
3. Results
Expression of the soluble PPAR LBDs in E. coli was
achieved using the pET15b expression vector as previously
described [23]. PPARK and PPARN consistently provided
Fig. 1. The £uorescent lipid probe, CPA, binds to PPARs. A: Increasing concentrations of human and mouse PPARQ LBDs were mixed with
CPA (500 nM). The resulting £uorescence is shown. B: Increasing concentrations of the mouse PPARQ LBD were mixed with CPA (200 nM).
The resulting £uorescence is shown. C: Puri¢ed PPAR LBDs were mixed with CPA (400 nM) in 25 mM Tris^HCl (pH 7.5). The £uorescence
values obtained using mouse PPARK and Q, and human PPARN are shown. Trypsinogen (5 WM) served as a negative control and Bm3R1, a
bacterial fatty acid sensor serves as a positive control. D: Increasing concentrations of puri¢ed Bm3R1 were mixed with either 500 nM or 3 WM
CPA. Saturation binding was not observed under either conditions suggesting the Kd of Bm3R1 binding to CPA is very high. Indeed, the Kd
of Bm3R1 binding to CPA is approximately 25 WM as judged by the ability of CPA to disrupt a Bm3R1/DNA complex in vitro (data not
shown).
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less soluble protein when compared to either mouse or human
PPARQ, and culture conditions for the induction of expression
of these proteins had to be performed at below 25‡C (data not
shown). The proteins were all highly puri¢ed by nickel-agar-
ose a⁄nity chromatography and assayed for their ability to
bind the £uorescent fatty acid CPA. When assayed for £uo-
rescence in the presence of 500 nM CPA, both mouse and
human PPARQ LBDs produced saturable increases in £uores-
cent signal (Fig. 1A). The binding e⁄ciency is similar for the
mouse and human proteins. This was con¢rmed in further
assays using 200 nM CPA where a Kd of 800 þ 100 nM was
obtained for mPPARQ (Fig. 1B) and this may be compared
with a Kd of 600 nM for the human isoform (Fig. 1A and
reference [23]).
The mouse PPARK LBD also produced £uorescence in the
presence of CPA, however the hPPARN did not produce sig-
ni¢cant £uorescence under these conditions (Fig. 1C). Weak
binding to hPPARN was, however, observed at high concen-
trations of protein and CPA (data not shown). Trypsinogen
used as a control produced no signi¢cant £uorescence even at
greater concentrations of CPA and protein than those used
for the PPAR proteins (data not shown). Bm3R1, a fatty acid
sensor from Bacillus megaterium, displayed weakly increasing
£uorescence over the protein concentrations studied (Fig. 1C).
Increasing the concentration of CPA to 3 WM gave much
stronger £uorescence with Bm3R1 but was not saturated at
the concentrations of protein used, indicating a Kd well above
the concentrations studied (Fig. 1D). Fatty acids disrupt the
binding of Bm3R1 to its operator DNA sequence and in vitro
DNA binding assays can be used to measure the concen-
trations at which Bm3R1 may interact with the fatty acids.
Such in vitro assays indicate that Bm3R1 has a Kd for CPA
of about 25 WM (C.Palmer, unpublished data). Bm3R1, how-
ever, binds other polyunsaturated fatty acids with a Kd of
around 1 WM [25,26]. In summary, the rank order of a⁄nities
for CPA are hPPARQvmPPARQsmPPARKsBm3R1s
hPPARNFtrypsinogen.
The £uorescent property of CPA was exploited in order to
determine whether or not the GLU282GLY mutant of mouse
PPARK is impaired in its ability to bind ligands. When the
wild type and mutant mPPARK proteins were compared it
was evident that the GLU282GLY mutant bound very poorly
to CPA (Fig. 2A), thus con¢rming the hypothesis that the
transcriptional e¡ects seen with this mutant are due to a dis-
ruption of the ligand binding properties of the encoded pro-
tein. However, due to the weak interaction of both forms of
PPARK it was impossible to quantitate the di¡erence in a⁄n-
ity. Also, it was possible that the mutation resulted in a pro-
tein defective in some non-speci¢c manner. In order to ad-
dress this issue and determine the speci¢city of the binding of
CPA, we used the £uorescent fatty acid 12-anthracene oleic
acid (12-AO). This fatty acid binds to the fatty acid-binding
pocket of the adipocyte fatty acid-binding protein in a manner
not a¡ected by mutations in the residues responsible for the
binding of the fatty acid carboxylic acid group [27]. This is
due to additional hydrophobic interactions between the hy-
drophobic anthracene moiety and the binding pocket. Bm3R1
has a Kd of 625 nM for 12-AO [23] and was therefore used as
a positive control in this assay. Bm3R1 appeared to bind
more e⁄ciently when compared to the PPAR proteins. All
the PPAR proteins bind to 12-AO with a similar e⁄ciency
(Fig. 2B), suggesting that the selectivity observed with CPA
was not due to the functionality of the expressed proteins.
In order to further investigate and quantify the role of the
glutamic acid in ligand binding, the cDNA encoding the hu-
Fig. 2. mPPARK-Glu282Gly displays reduced binding to CPA. A:
Increasing concentrations of puri¢ed LBDs were mixed with CPA
(400 nM). The £uorescence values obtained using mouse PPARK
and the mPPARK-Glu282Gly are shown. A reduced binding of the
GLU282GLY mutant form of mPPARK relative to the wild type
form is evident. B: Puri¢ed PPAR LBDs (2 WM) were mixed with
12-AO (1 WM) in 25 mM Tris^HCl (pH 7.5). The resulting £uores-
cence is shown.
Fig. 3. Helix 3 is a conserved ligand binding site for all nuclear re-
ceptors. Shown is an alignment of the helix 3 sequences from sev-
eral nuclear receptors. Known ligand interacting residues are under-
lined and conserved regions of PPAR helix 3 are boxed. The
conserved glutamic acid is shown in bold.
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man PPARQ LBD was modi¢ed using site directed mutagen-
esis to encode a glycine substitution at position 291.
GLU291GLY corresponds to the GLU282GLY mutation al-
ready studied in mouse PPARK (Fig. 3). This residue is con-
served within all members of the PPAR subfamily and there-
fore it is possible that it may a¡ect the binding of many
PPAR ligands (Fig. 3).
The wild type and mutant forms of hPPARQ were then
prepared and assayed for £uorescence in the presence of
CPA (Fig. 4A). It is apparent that the wild type protein yields
£uorescent signal at much lower protein concentrations than
observed for the mutant protein; thus, demonstrating that the
GLU291GLY substitution attenuates the physical binding of
fatty acid ligands to PPARQ as well as to PPARK. The values
obtained using 150 nM CPA were 560 þ 70 nM for the wild
type and 1.82 þ 0.3 WM for the mutant protein. The assays
were also performed for the mutant at 300 nM due to the
higher apparent Kd of this protein (Fig. 4B). This analysis
gave a Kd of 1.9 þ 0.19 WM in good agreement with the assays
performed with 150 nM CPA. Therefore, there is a 3.5 fold
di¡erence in apparent Kd for CPA between the wild type and
mutant proteins.
PPARQ is a high a⁄nity receptor for the thiazolidinedine
group of insulin sensitising drugs such as troglitazone and
BRL49653. In order to determine whether the GLU291GLY
substitution a¡ected the binding of synthetic drugs, we per-
formed rapid ¢lter binding studies using I125-labelled
Fig. 4. PPARQ-Glu291Gly displays a reduced e⁄ciency of binding
for CPA. Increasing concentrations of mutant and wild type pro-
teins were added to CPA (150 nM) as before. Higher concentrations
of the mutant protein were required to obtain a £uorescent signal
when compared to the wild type protein. Both proteins were of sim-
ilar purity and yield as judged by SDS-PAGE (data not shown).
PPARQ-Glu291Gly assayed in the presence of 300 nM CPA.
Fig. 5. PPARQ-Glu291Gly has a reduced binding a⁄nity for the the
high a⁄nity drug, SB236636. Puri¢ed mutant and wild type PPAR
LBDs were incubated with increasing concentrations of I125 labelled
SB236636 and assayed by rapid ¢ltration as described in Section 2.
Saturating binding was observed (A). Scatchard analysis of the wild
type (B) and mutant protein (C) binding to SB236636 reveals that
the mutant receptor displays about a four fold reduction in binding
a⁄nity for SB236636.
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SB236636 (Fig. 5). Scatchard analysis of the binding of wild
type hPPARQ to SB236636 revealed a Kd of 23 nM. Similar
experiments using the mutant protein revealed a Kd of 100
nM. In both cases the receptor concentration (x-axis inter-
cept) is very low compared to the amount of recombinant
protein added. This is not due to inactive receptor in the
preparations as we have con¢rmed the stoichiometry of bind-
ing of human PPARQ protein to CPA as being 1 molecule of
CPA per monomer unit of PPARQ [23]. This underestimate of
receptor concentration is therefore, presumably, due to the
time-dependent dissociation of ligand during the ¢ltration
process. The Scatchard analysis revealed that the mutant re-
ceptor had a higher capacity for ligand than the wild type
mutation (compare Fig. 5B and C). This again indicates
that the mutant receptor is not defective in a non-speci¢c
manner. These results demonstrate that glutamic acid 291 is
an important residue in the binding of high a⁄nity drugs as
well as for the binding of fatty acids.
4. Discussion
The involvement of a conserved glutamic acid in the ligand
binding of PPARs has been con¢rmed using a £uorescent
fatty acid ligand in both mPPARK and hPPARQ. This residue
also in£uences the binding of the high a⁄nity ligand,
SB236636. It appears from the crystal structures of oestrogen
receptor (ER), retinoic acid receptor (RAR) and thyroid hor-
mone receptor (TR) that this region is involved in the binding
of the carboxylic acid functions of their respective ligands.
This is supported by the fact that his mutation does not a¡ect
the binding of the hydrophobic probe, 12-anthracene oleic
acid. Our data would suggest that the glutamic acid may be
directly involved in the coordination of fatty acid carboxylic
acid groups. The role for glutamic acid in the coordination of
carbonyl groups has recently been shown to be important in
the binding of oestrogen to its nuclear receptor. In the ER,
glutamic acid 353 is the corresponding residue to GLU291
PPARQ (Fig. 3). Glu-353 of ER cooperates with water and
arginine 394 to form hydrogen bonds with the C3 carbonyl
group of oestrogen [28]. However, this role for Glu-291 has
not been observed in the recent crystal structures of hPPARQ
containing the high a⁄nity ligand BRL 49653 or the crystal
structure of eicosapentanoic acid (EPA) bound to PPARN
[29,30]. In both cases hydrogen bonding of the compounds
does not directly involve this residue. The structure proposed
for the PPARs has shown that the carbonyl groups are hydro-
gen bonded to His-323 and His-449 (Fig. 6). These interac-
tions are also utilised in the binding of EPA to PPARN and
appear to be required for the stabilisation of the ‘charge
clamp’ that binds the co-activator proteins thus providing
the molecular basis for ligand activated transcription.
In the binding of EPA to PPARN, several helix 3 residues
have hydrophobic interactions with the region of the acyl
chain immediately preceding the carboxylate terminus. Most
importantly, the acid-head group is held in place by a hydro-
phobic interaction with threonine 289 which is less than one
helical turn from glutamic acid 291. It would therefore be
possible that substitution of alanine for glutamic acid may
interfere with this interaction. This may explain the di¡erences
observed in ligand binding and the lack of e¡ect that this
mutation has on the binding of 12-anthracene oleic acid.
However, there is an alternative explanation for the role of
this residue in ligand binding based on the observed orienta-
tion of Glu-291 in the crystal structures. In both holo- and
apo-PPARQ, glutamic acid 291 appears to form an upper ‘jaw’
for the rather open space between H3 and the L-sheet which
has been recently proposed to be the ligand entry site [29,30].
This ‘jaw’ has a glutamic acid 343 forming the lower portion
and these two residues may provide a trapping mechanism for
the acidic fatty acids. This evokes a ‘lobster pot’ type ligand
entry model as opposed to the previously proposed ‘trap door’
model in which the AF2 helix would be pulled ‘closed’ to-
wards helix 3 upon entry of a fatty acid. The lack of move-
ment of the AF2 domain between apo- and holo-PPAR struc-
tures would also suggest that the fatty acid may enter from
the other ‘lobster pot’ entry site. Further site-directed muta-
genesis and biophysical analysis is required to determine the
relevance of these two binding models.
In summary, glutamic acid 291 is a conserved amino acid
between PPARs that is involved in the binding of ligands;
however, this residue is not in itself a ligand contact residue.
This study provides the ¢rst experimental evidence for the
binding of ligands through a novel entry site that was ¢rst
visualised by X-ray crystallography.
Acknowledgements: We would like to thank Dr Steve Smith and Dr
Greg Murphy at SmithKline Beecham for their advice and for the
radioligand, SB236636. This work was supported by a BBSRC ROPA
Award No. MOLO4650
References
[1] Issemann, I. and Green, S. (1990) Nature 347, 645^650.
[2] Palmer, C.N.A., Hsu, M.H., Gri⁄n, K.J., Raucy, J.L. and John-
son, E.F. (1998) Mol. Pharmacol. 53, 14^22.
[3] Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne,
B. and Wahli, W. (1999) J. Clin. Invest. 103, 1489^1498.
[4] Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz,
D.L., Fernandez, S.P., Westphal, H. and Gonzalez, F.J. (1995)
Mol. Cell. Biol. 15, 3012^3022.
[5] Peters, J.M., Cattley, R.C. and Gonzalez, F.J. (1997) Carcino-
genesis 18, 2029^2033.
[6] Lim, H., Gupta, R.A., Ma, W.G., Paria, B.C., Moller, D.E.,
Fig. 6. Glu-291 and Glu-343 form a hydrophilic jaw around the
novel ligand entry site proposed for PPARQ. The structure of the
high a⁄nity ligand, rosiglitazone, bound to hPPARQ was visualised
using RASMAC version 2.6 from the coordinates supplied as
2PRG.pdb. The high a⁄nity ligand, rosiglitazone, is shown in blue.
FEBS 23048 9-12-99 Cyaan Magenta Geel Zwart
M. Causevic et al./FEBS Letters 463 (1999) 205^210 209
Morrow, J.D., DuBois, R.N., Trzaskos, J.M. and Dey, S.K.
(1999) Genes Dev. 13, 1561^1574.
[7] Saltiel, A.R. and Olefsky, J.M. (1996) Diabetes 45, 1661^1669.
[8] Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J.,
Witztum, J.L., Auwerx, J., Palinski, W. and Glass, C.K. (1998)
Proc. Natl. Acad. Sci. USA 95, 7614^7619.
[9] Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. and Glass, C.K.
(1998) Nature 391, 79^82.
[10] Mueller, E., Sarraf, P., Tontonoz, P., Evans, R.M., Martin, K.J.,
Zhang, M., Fletcher, C., Singer, S. and Spiegelman, B.M. (1998)
Mol. Cell 1, 465^470.
[11] Sarraf, P., Mueller, E., Jones, D., King, F.J., DeAngelo, D.J.,
Partridge, J.B., Holden, S.A., Chen, L.B., Singer, S., Fletcher, C.
and Spiegelman, B.M. (1998) Nat. Med. 4, 1046^1052.
[12] Sarraf, P., Mueller, E., Smith, W.M., Wright, H.M., Kum, J.B.,
Aaltonen, L.A., de la Chapelle, A., Spiegelman, B.M. and Eng,
C. (1999) Mol. Cell 3, 799^804.
[13] Tontonoz, P., Graves, R.A., Budavari, A.I., Erdjument, B.H.,
Lui, M., Hu, E., Tempst, P. and Spiegelman, B.M. (1994) Nu-
cleic Acids Res. 22, 5628^5634.
[14] Tontonoz, P., Hu, E. and Spiegelman, B.M. (1994) Cell 79, 1147^
1156.
[15] Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I. and Spiegel-
man, B.M. (1994) Genes Dev. 8, 1224^1234.
[16] Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman,
B.M. and Evans, R.M. (1995) Cell 83, 803^812.
[17] Kliewer, S.A., Lenhard, J.M., Willson, T.M., Patel, I., Morris,
D.C. and Lehmann, J.M. (1995) Cell 83, 813^819.
[18] Lehmann, J.M., Moore, L.B., Smith, O.T., Wilkison, W.O., Will-
son, T.M. and Kliewer, S.A. (1995) J. Biol. Chem. 270, 12953^
12956.
[19] Jiang, C., Ting, A.T. and Seed, B. (1998) Nature 391, 82^86.
[20] Hsu, M.H., Palmer, C.N.A., Gri⁄n, K.J. and Johnson, E.F.
(1995) Mol. Pharmacol. 48, 559^567.
[21] Palmer, C.N., Hsu, M.H., Muerho¡, A.S., Gri⁄n, K.J. and
Johnson, E.F. (1994) J. Biol. Chem. 269, 18083^18089.
[22] Forman, B.M., Chen, J. and Evans, R.M. (1997) Proc. Natl.
Acad. Sci. USA 94, 4312^4317.
[23] Palmer, C.N.A. and Wolf, C.R. (1998) FEBS Lett. 431, 476^480.
[24] Young, P.W., Buckle, D.R., Cantello, B., Chapman, H., Clap-
ham, J.C., Coyle, P.J., Haigh, D., Hindley, R.M., Holder, J.C.,
Kallender, H., Latter, A.J., Lawrie, K., Mossakowska, D., Mur-
phy, G.J., Cox, L.R. and Smith, S.A. (1998) J. Pharmacol. Exp.
Ther. 284, 751^759.
[25] English, N., Palmer, C.N.A., Alworth, W.L., Kang, L., Hughes,
V. and Wolf, C.R. (1997) Biochem. J. 316, 279^283.
[26] Palmer, C.N.A., Axen, E., Hughes, V. and Wolf, C.R. (1998)
J. Biol. Chem. 273, 18109^18116.
[27] Sha, R.S., Kane, C.D., Xu, Z., Banaszak, L.J. and Bernlohr,
D.A. (1993) J. Biol. Chem. 268, 7885^7892.
[28] Brzozowski, A.M., Pike, A.C., Dauter, Z., Hubbard, R.E., Bonn,
T., Engstrom, O., Ohman, L., Greene, G.L., Gustafsson, J.A.
and Carlquist, M. (1997) Nature 389, 753^758.
[29] Xu, H.E., Lambert, M.H., Montana, V.G., Parks, D.J., Blan-
chard, S.G., Brown, P.J., Sternbach, D.D., Lehmann, J.M.,
Wisely, G.B., Willson, T.M., Kliewer, S.A. and Milburn, M.V.
(1999) Mol. Cell 3, 397^403.
[30] Nolte, R.T., Wisely, G.B., Westin, S., Cobb, J.E., Lambert,
M.H., Kurokawa, R., Rosenfeld, M.G., Willson, T.M., Glass,
C.K. and Milburn, M.V. (1998) Nature 395, 137^143.
FEBS 23048 9-12-99 Cyaan Magenta Geel Zwart
M. Causevic et al./FEBS Letters 463 (1999) 205^210210
